@knoppbio.com
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Knopp Biosciences is a pioneering brand dedicated to revolutionizing the field of medicine. With a strong focus on immunological and neurological diseases, Knopp has an impressive 18-year track record in drug discovery. As a privately held company, they manage a diverse portfolio of equity securities and future product royalties.
One of their flagship products is dexpramipexole, an oral small molecule currently under development for eosinophilic asthma. This groundbreaking treatment is being advanced by Areteia Therapeutics, Inc., a portfolio company of Bain Capital Life Sciences. Additionally, Knopp's clinical stage Kv7 platform offers small-molecule treatments for epilepsy and other hyperexcitability disorders.
These cutting-edge therapies have been acquired by Biohaven Pharmaceuticals, a leading player in the pharmaceutical industry. Excitingly, Knopp is launching a new investor portal in Spring 2023, providing members with access to their latest newsletters, financial statements, and exclusive proprietary information. Knopp Biosciences is at the forefront of life-changing medicine, dedicated to improving the health and well-being of individuals worldwide
Company Type
Privately Held
Company Size
2-10
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online